THE ENIGMA OF FRAGILITY FRACTURE WITH NORMAL BONE MASS; EXPERIENCE OF A LIAISON SERVICE FRACTURE UNIT

Antonio Naranjo, Soledad Ojeda, Aida Saavedra, Cristina Sepúlveda, Amparo Molina, Tatiana Marrero, María Pino Alonso, Margarita Ramírez, Nieves Martín, Alicia Olivarés, Carlos Rodríguez-Lozano, Las Palmas de Gran Canaria, Rheumatology, Las Palmas de Gran Canaria, Spain; Hospital Universitario de Gran Canaria Dr Negrín, Rheumatology, LAS PALMAS DE G C, Spain; Hospital Universitario de Gran Canaria Dr Negrín, Radiology, LAS PALMAS DE G C, Spain; Hospital Universitario de Gran Canaria Dr Negrín, Clinical Analysis, LAS PALMAS DE G C, Spain; Hospital Universitario de Gran Canaria Dr Negrín, Rheumatology, LAS PALMAS DE G C, Spain; Hospital Universitario de Gran Canaria Dr Negrín, Rehabilitation, LAS PALMAS DE G C, Spain; Gerencia de atención primaria de Gran Canaria, LAS PALMAS DE G C, Spain

Background: The enigma of fragility fracture with normal bone mass; Experience of a Liaison Service Fracture Unit

Objectives: To describe the characteristics of patients with fragility fracture and normal DXA treated in an FLS unit.

Methods: Prospective 6-year observational study of a FLS fracture unit. Demographic variables, FRAX items, DXA and TBS were collected. The characteristics of patients with normal and abnormal DXA are described. The statistical analysis was performed by means of a descriptive, comparing the normal DXA; osteopenia/osteoporosis groups by means of contingency tables, Fisher’s exact test. Student’s t test or ANOVA, as appropriate, as well as regression analysis.

Results: 1,631 patients were included, 205 with normal DXA (12.5%), 747 with osteopenia (45.8%) and 680 with osteoporosis (41.6%). Patients with normal DXA were characterized by a higher percentage of males, a younger age and a higher BMI. Hip fracture was less frequent in patients with normal DXA, while the frequency of other fractures was higher. The frequency of previous fracture, history of hip fracture of the parents and secondary osteoporosis was lower in patients with normal DXA. The TBS and FRAX values were higher in the cases of normal DXA compared to osteopenia and osteoporosis. In the multiple regression analysis, excluding TBS <1,230 as a dichotomous variable (N = 451 cases) remained significant age (OR 1.03; 1.03-1.06), sex (OR 2.48; 1.71-3.58), BMI (OR 0.91; 0.89-0.94), and parent hip fracture (OR 1.99; 1.11-3.58). Including TBS <1,230 as a dichotomous variable (N = 451 cases) remained significant age (OR 1.03; 1.00-1.06), sex (OR 3.58; 1.81-7.10) and TBS (OR 5.23; 1.55-17.68).

Conclusions: Patients with fragility fracture and normal bone mass are younger, with more frequent males and with BMI and higher TBS values. Acknowledgement: Fabiola Santana y Carmen Alonso

Disclosure of Interests: Antonio Naranjo Grant/research support from: Amgen, Consultant for: UCB, Speakers bureau: Amgen, Soledad Ojeda Grant/research support from: AMGEN, Speakers bureau: AMGEN, Aida Saavedra: None declared, Cristina Sepúlveda: None declared, Amparo Molina Speakers bureau: AMGEN, Tatiana Marrero: None declared, María Pino Alonso: None declared, Margarita Ramírez: None declared, Nieves Martín: None declared, Alicia Olivarés: None declared, Carlos Rodríguez-Lozano: None declared DOI: 10.1136/annrheumdis-2019-eular.5077

EFFECTIVENESS AND SAFETY OF BISPHOSPHONATES IN THE TREATMENT OF SECONDARY OSTEOPOROSIS CHILDREN

Julia Ferreiro Turrión, Rocío Galindo Zavala, Esmeralda Núñez Cuadros, Gisela Diaz-Cordobes, Laura Martín Pedraz, Antonio Urdí Cardona. Hospital Regional Universitario de Málaga, Málaga, Spain

Background: Prevalence of secondary osteoporosis (SO) in children is an ongoing challenge, due to the rise in life expectancy of chronic diseases and the bone toxicity medication usage. Bisphosphonates (BF) has been stated as an alternative therapy, although studies targeted children are few.

Objectives: The goal was to establish the effectiveness and safety of bisphosphonate therapy in children with SO.

Methods: A retrospective study of BF treatment in children (<16 years) with SO at a Pediatric Reumathology Unit from 2015 to 2018. Descriptive statistics were performed to examine anthropometric measurements, clinical features, diagnoses and treatment received. We measured bone mineral density by dual-energy x-ray absorptiometry and we expressed the results as adjusted for height-for-age Z-score (HAZ).

Results: In our study 12 patients were treated with BF, three of them with two different type. Table 1 shows the descriptive data. The HAZ and the fracture rate per year after a year of treatment were expressed as adjusted for height-for-age Z-score (HAZ). We assessed the treatment outcome by the change of HAZ after a year of treatment and the decreasing fractures rate per year. Afterwards we made a bivariate analysis to identify related factors with effectiveness and safety of bisphosphonates. Values of p<0.1 were considered statistically significant.

Table 1. Descriptive analysis

<table>
<thead>
<tr>
<th>Variable</th>
<th>n (%)</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>9 (75)</td>
<td>9.9 ± 0.8</td>
</tr>
<tr>
<td>Age (years)</td>
<td>9.9 ± 0.8</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>21.3 ± 2.6</td>
<td></td>
</tr>
<tr>
<td>HAZ SO at a Pediatric Reumathology Unit from 2015 to 2018.</td>
<td>21.3 ± 2.6</td>
<td></td>
</tr>
<tr>
<td>Secondary osteoporosis, yes (%)</td>
<td>11 (92)</td>
<td></td>
</tr>
<tr>
<td>Bone mineral density by dual-energy x-ray absorptiometry</td>
<td>21.3 ± 2.6</td>
<td></td>
</tr>
<tr>
<td>Before treatment fracture, yes (%)</td>
<td>11 (92)</td>
<td></td>
</tr>
<tr>
<td>Z score* before treatment, yes (%)</td>
<td>21.3 ± 2.6</td>
<td></td>
</tr>
<tr>
<td>Age at first fracture (years), yes (%)</td>
<td>21.3 ± 2.6</td>
<td></td>
</tr>
</tbody>
</table>

Acknowledgement: Fabiola Santana y Carmen Alonso

Disclosure of Interests: Antonio Naranjo Grant/research support from: Amgen, Consultant for: UCB, Speakers bureau: Amgen, Soledad Ojeda Grant/research support from: AMGEN, Speakers bureau: AMGEN, Aida Saavedra: None declared, Cristina Sepúlveda: None declared, Amparo Molina Speakers bureau: AMGEN, Tatiana Marrero: None declared, María Pino Alonso: None declared, Margarita Ramírez: None declared, Nieves Martín: None declared, Alicia Olivarés: None declared, Carlos Rodríguez-Lozano: None declared DOI: 10.1136/annrheumdis-2019-eular.22727
The change at HAZ and the before treatment fractures rate per year (r=0.57; p=0.07) were directly proportional. Also, the change at HAZ was inversely proportional to the before treatment Z-score (r=-0.53; p=0.09) and the BF starting age (r=-0.53; p=0.09).

The decrement of fractures rate per year showed a statistical significant relationship with BMI percentile (r=0.48; p=0.08), the starting treatment age (r=-0.53; p=0.05) and before treatment fractures rate per year (r=0.941; p=0.001).

Three patients experienced adverse effects (20%). Three related to zoledronate use: two of them showed flu-like syndrome after first infusion and the other asymptomatic hypocalcemia. In another patient the treatment with alendronate was ended due to gastrointestinal intolerance. There was not significant relationship between adverse effects and our study variables.

Two patients died during the treatment due to their underlying disease complications.

**Conclusion:** BF are an effective medication for SO. The treatment outcome exhibits to be better with a good nutritional status, younger age and at more severe forms of the disease. Additionally, they are showing just minor adverse effects but often.

**REFERENCES**


**Disclosure of Interests:** Julia Ferrero Turrion: None declared, Rocío Galindo Zavala Grant/research support from: NOVARTIS, ABBVIE (ALWAYS AS SPEAKER), Speakers bureau: NOVARTIS, ABBVIE, Esmer-aldia Núñez Cuadros Grant/research support from: NOVARTIS, ABBVIE, ROCHE (ALWAYS AS SPEAKER), Speakers bureau: NOVARTIS, ABBVIE, ROCHE, Gisela Díaz-Cordobes Grant/research support from: ABBVIE, ROCHE (ALWAYS AS SPEAKER), Speakers bureau: ABBVIE, ROCHE, Laura Martín Pedraz: None declared, Antonio Urda Cardona Grant/research support from: PFIZER (ALWAYS AS SPEAKER), Speakers bureau: PFIZER

**DOI:** 10.1136/annrheumdis-2019-eular.7730

**OSTEOPOROSIS IN MEN**

Vitaliy Polyakov1, Gleb Kravtsov1, J Polyakov2, B Zavodovskiy2, 1Volgograd State Medical University, Volgograd, Russian Federation; 2Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky», Volgograd, Russian Federation

**Background:** Careful attention to postmenopausal osteoporosis (OP) leads to an understimation of this problem in men.

**Objectives:** To assess the frequency of bone mineral density reduction (BMD) in men referred for examination, analysis of bone mineralization disorders in men at different age periods, the main reasons for referral (FMRP).

**Methods:** During the year, a two-energy X-ray absorption osteodensitome-try (LUNAR XP, USA) was examined by 2,731 patients according to a standard program.

**Results:** Among the 2,731 patients referred for examination, the proportion of men is 5%, men over 60 years old are 2%, male children and teenagers are 0.29%. Normal BMD was detected in 31.88%, low bone mass (LBM) - in 39.86%, OP - in 28.26%. 60.14% (83 people) - men of young and middle age. NCM was detected in 33 men, OP - in 14. In 8 - severe form. Reduced BMD patients revealed the presence of serious underlying disease (anklosing spondylidy, rheumatoid arthritis (RA), systemic lupus erythematosus, diabetes mel- litus I type, diffuse toxic goiter disease operated stomach, ulcerative colitis, chronic autoimmune hepatitis and alcoholic hepatic toxicity with outcome in cirrhosis of the liver, bronchial asthma (BA), alcoholism).

Elderly and senile men among the surveyed were 55 people (39.86%), LBM - in 22 of them, OP - in 25. Low traumatic fractures in the anamnesis in this group of patients were detected in 13 of 55. In 6 - multiple vertebral fractures, in 2 - multiple repeated fractures of tubular bones. Secondary causes of a decrease in BMD were detected only in 5 out of 55 (9.09%) men aged 60 years and older (RA, BA, idiopathic alveolitis, liver cirrhosis; all currently or with a history of glucocorticoid therapy).

Normal BMD was detected in 44 men. Up to 59, their number was 36 people (81.8%), 60 years and older - 2 (18.2%). The majority of men with normal BMD indices were sent for examination by dentists, endocrinologists, orthopedic traumatologists. 5 adolescents with BMD in accordance with normal age criteria BMD had repeated traumatic bone fractures in history (fractures during sports, wrestling, football).

**Conclusion:** Unlike women, men do not pay enough attention to the preven-tion of OP, often use expensive products in limited quantities, do not take calcium preparations for prophylactic purposes. A high percentage of the population is characterized by low physical activity. Men more often than women abuse alcohol and smoking.

OP occurs without obvious clinical manifestations until the moment of fracture of the skeleton bones, primary care physicians and hospitals have low alertness for the detection of OP in men. FRAX (fracture risk assessment tool) makes it easy to calculate the probability of a 10-year risk of fractures and identify men at high risk for further examination. The urgency of the problem is due to the increase in the average life expectancy of a modern person.

**REFERENCES**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7730

**AB0846**

**INCIDENCE RATES OF OSTEOPOROSIS(OP) RISK FACTORS IN A LARGE URBAN LONDON BOROUGH**

Rozyan Rajak1, Amanda Perren1, Suma Mahendrakar2, Morrina Zamani3, Li Elaine4, Michael Kotrba5, Amanda Humphreys2, Joseph Rehman2, Wallace Tan2, Fatih A. Al-Jehani6, Suzy Peerman7.

**Background:** Identification of osteoporosis risk factors(OPRFs) is a neces-sary part of assessing fracture risk and treating patients with OP. Incidence rates of OPRFs are variably reported in the literature. Patients seen in OP clinics tend to have a higher risk of fractures compared to those managed in primary-care hence the need for closer scrutiny of their OPRFs. In some instances, managing modifiable OPRFs may form the principle part of the patient’s management plan.

**Objectives:** We examined the rates of OPRFs in patients attending the Bone Health Clinic at Croydon Health Services NHS Trust.

**Methods:** Retrospective review of OP patients seen between February-June 2018 at Purley Memorial Hospital and assessed for presence of OPRFs including: demographics,BMI,early menopause,late menarche,nulling-a,secondary medical conditions,medicines,family history of OP/parental hip fracture,recurrent fragility fractures(FFs) and lifestyle OPRFs(smoking,alcohol,low calcium intake,sedentary).

**Results:** 201 patients were included. Mean age was 70-years-old (range37-96), with approximately 9.1 female:male ratio. Mean BMI was 23(normal) with approximately 20% being <18.5(underweight). 25.5%(46/180-females) experienced fractures on or before the age of 55 years (15/180 had late menarche(>16-years). Of the 25.5% with early meno-pause, only 13%(6/46) had been offered HRT. 17% of women were nuli-parous. Of the medical conditions, thyroid disease was the most commonly reported(18%) with a third of these being newly diagnosed in clinic. Coeliac was identified in 7.5% with 5% newly diagnosed. 2% had newly diagnosed haematological disorders (MGUS,Myeloma,Lymphoma). Only 8 patients had 2-or-more diagnoses at the same time. Almost 40% had a family history of OP, 19% history of parental hip fracture and 15% had both. The majority 66.7%(134/201) had experienced a previous FF with 36% having suffered 2 or more. 16%(32/201) had experienced